ASX Announcement

Director Resignations

28 October 2020 –Race Oncology Limited (ASX: RAC) wishes to advise that Dr Bill Garner and Mr Chris Ntoumenopoulos have resigned from the roles of Non-Executive Director.

Non-Executive Chairman, Dr John Cullity commented, "Bill and Chris as founding directors have been an asset to Race and we thank them both for their longstanding commitment to the Company. We are immensely grateful of the service provided and contributions they have made, both as Directors and shareholders, and wish them both all the best for the future."

Dr Bill Garner commented, "Since founding Race in 2016, Chris and I have watched Race grow; progress the strategy of bringing Bisantrene back to the clinic and now with current clinical data and new strategic prospects, the Company is prospering. Given the time commitments required of other ventures that we're each involved with, we are stepping out at a time when the business is in a solid funding position and a strong state. We both wish the Company every success."

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Phillip Lynch, CEO & Managing Director

phillip.lynch@raceoncology.com

John Cullity, Executive Chairman

john.cullity@raceoncology.com

Media contact:

Jane Lowe, IR Department

+ 61 411 117 74